SPARROW-QUANTUM
14.3.2024 08:06:34 CET | Business Wire | Press release
ORCA Computing, Pixel Photonics, Sparrow Quantum, and the Niels Bohr Institute (NBI) announce their collaboration on the Eurostars project 'SupremeQ.' This landmark initiative brings together quantum experts from the United Kingdom, Germany, and Denmark with a shared goal of accelerating the development and commercialization of photonic quantum computing technologies to deliver quantum advantage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240313844049/en/
ORCA PT-1 computer in assembly room (Photo: Business Wire)
Supported by Eurostars, a European funding program dedicated to assisting R&D-performing SMEs in developing marketable innovative products, processes, and services, the SupremeQ project will harness world-leading expertise. It will draw upon single-photon sources from Sparrow Quantum and NBI, single-photon detectors from Pixel Photonics, and full-stack photonic quantum computing system architecture from ORCA Computing. By uniting efforts, the SupremeQ consortium aims to drive breakthrough innovation in photonic quantum computing, paving the way for quantum advantage.
According to a report by Fortune Business Insights, the quantum computing market is forecasted to reach $6.5 billion by 2030 with a CAGR of 32.1%1. With a broad range of potential application areas offering significant advantages over current classical computations. The SupremeQ project aims to address the needs of this growing market demand for quantum computing capabilities by addressing key challenges such as system engineering for scale, high acquisition, and operation costs, as well as the need for specialized expertise.
By pioneering solutions for photonic quantum computing, the project aims to unveil groundbreaking innovations in performance, packaging, and system integration. Sparrow Quantum’s single-photon sources and Pixel Photonics detectors will be engineered to co-exist within a single cryostat, marking a breakthrough in quantum computing infrastructure. With reduced complexity and enhanced component proximity, this crucial milestone heralds the path to multiplying qubits while offering considerable manufacturability and cost advantages.
ORCA Computing will draw upon its deep knowledge in quantum photonic system architecture. This expertise will be used to integrate these developments and demonstrate state-of-the-art photon processing efficiencies and reconfigurability within a standard data center rack.
These advancements are necessary for the commercialization of quantum computers to reach advantage over classical computing systems signifying a significant leap toward achieving universal fault-tolerant quantum computing.
As the quantum computing market continues to evolve, the consortium is confident that their innovative SupremeQ solutions will generate considerable interest, driving diverse applications and accelerating the widespread adoption of quantum technologies across industries well beyond the conclusion of the Eurostars program.
Consortium partners share their perspectives on the groundbreaking developments of the project:
"I envision SupremeQ as a symphony of quantum brilliance, with each partner playing a unique instrument,” stated Dr. Kurt Stokbro, CEO of Sparrow Quantum. “Together, we're composing a masterpiece that I believe will make some noise around the world."
"The advancements made possible through the SupremeQ project represent a significant leap forward in quantum computing technology," stated Nicolai Walter, CEO of Pixel Photonics. "By combining cutting-edge components and innovative architecture, we will be well-positioned to redefine the boundaries of what is possible in quantum computing."
"We are delighted to announce this new partnership with two other leading European firms,” affirmed Richard Murray, CEO of ORCA Computing. "With its unparalleled performance, the outcome of this project will spearhead new frontiers in hybrid quantum-classical computation, driving significant advancements in machine learning and optimization."
“We are thrilled to collaborate with esteemed industry partners on the SupremeQ project, which represents a significant step forward in quantum computing innovation," says Peter Lodahl, Professor at the Niels Bohr Institute.
Explore the SupremeQ project and how it will revolutionize the industry by contacting the consortium partners for more information.
Source 1: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/quantum-computing-market-104855
About ORCA Computing:
ORCA Computing, headquartered in London, UK with offices in the United States and Canada, is a leading developer and provider of full-stack photonic quantum computing systems. Established in 2019 and originating from the University of Oxford, the company provides an innovative approach to photonic quantum computing. Anchored in a modular optical fiber-based architecture, ORCA’s proprietary methods of manipulating the time, frequency and switching of single photons paves the way for quantum computing using significantly fewer components. ORCA Computing has successfully delivered numerous on-premises quantum computers to leading customers including the UK Ministry of Defence and the Poznan Supercomputing and Networking Center.
For more information, please visit www.orcacomputing.com.
About Pixel Photonics:
Pixel Photonics is a German deep-tech startup that has developed a unique approach to integrate SNSPDs (Superconducting Nanowire Single Photon Detectors) on a chip waveguide. Pixel Photonics combines the superior features of SNSPDs with the versatility of an integrated photonic platform to provide highly parallelized, efficient and ultra-fast single-photon detection. Waveguide integration enables the use of SNSPDs for photon counting, paving the way for high-performance and scalable photonic quantum computing. The Pixel Photonics team consists of 36 employees from 8 different countries.
Learn more about Pixel Photonics and the WI-SNSPD technology at www.pixelphotonics.com.
About Sparrow Quantum:
Sparrow Quantum, headquartered in Copenhagen, Denmark, is a leading provider of single-photon components enabling the photonic quantum revolution. Our flagship product, a deterministic single-photon source, sets industry standards and earns acclaim from leading quantum technology groups worldwide. With roots in over two decades of pioneering research at the Niels Bohr Institute, our technology seamlessly integrates with leading photonic quantum computing platforms and communication systems. Our dedication to advancing light-matter interfaces for quantum technologies ensures we deliver essential components for scaling up advanced quantum technology applications in information processing and communication.
Discover more about Sparrow Quantum at www.sparrowquantum.com.
About the Niels Bohr Institute, Copenhagen University:
At the Niels Bohr Institute, University of Copenhagen, we research and teach in a broad spectrum of physics areas: quantum computers and communication, astrophysics, particle physics, computational physics, solid state physics, climate and geophysics, and biophysics. In the past decade, our research in solid-state physics and quantum optics has continuously intensified with several new, large research centres. Among the latest is the Copenhagen Center for Biomedical Quantum Sensing, which will research in the development of ultra-sensitive sensors for the early detection of diseases. Last year, the Novo Nordisk Foundation Quantum Computing Program was also inaugurated, the goal of which is to develop a fully functional quantum computer within the next 12 years.
For more information, please visit www.nbi.ku.dk.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240313844049/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom